Global BCG Vaccine Market is valued approximately at USD 23.25 million in 2019 and is anticipated to grow with a healthy growth rate of more than 4.53% over the forecast period 2020-2027. The Bacillus Calmette-Gurin (BCG) vaccine is the only vaccine available to prevent tuberculosis (TB). In countries with a high prevalence of tuberculosis, one dosage is prescribed for babies close to the time of birth. However, in regions where tuberculosis is rare, only children at high risk are usually immunized, while confirmed cases of tuberculosis are directly screened and administered. The vaccine also immunizes people not diagnosed ith tuberculosis and are not vulnerable to drug-resistant tuberculosis. Rising prevalence of tuberculosis, especially in developing and underdeveloped countries, as well as technological advances in the field of vaccine science, are the major factors driving the growth of the BCG vaccine market. Also, as per the Global Tuberculosis Report of 2018, the majority of TB patients (66%) live in one of eight countries: India (27%), China (9%), Indonesia (8%), the Philippines (6%), Pakistan (5%), Nigeria (4%), Bangladesh (4%) or South Africa (3 percent). In addition, growing birth rates across the world, especially in China and India, are leading to substantial demand growth. Moreover, cohesive government policies and a global focus on immunization services are pushing the growth of the market upwards. Untapped investment markets in developing regions are projected to have several possibilities for market expansion.
However, side effects of BCG vaccines impede the growth of the market over the forecast period of 2020-2027.

The regional analysis of global BCG Vaccine market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia pacific is the leading/significant region across the world in terms of market share owing to the high prevalence of TB in Asian countries such as India, Pakistan, Bangladesh and others. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rapidly increasing government efforts in form of vaccination drives would create lucrative growth prospects for the BCG Vaccine market across Asia-Pacific region.

Major market player included in this report are:
Merck & Co. Inc.
Sanofi Pasteur
Japan BCG Laboratory
China National Biotech Group
Serum Institute of India Pvt. Ltd.
InterVax Ltd.
GreenSignal Bio Pharma Limited (GSBPL)
Statens Serum Institute
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Immune BCG
Therapy BCG
By Demographics:
Pediatrics (0-18 Years)
Adults (19-35 Years)
By Application:
Hospitals
Clinics
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018
Base year 2019
Forecast period 2020 to 2027

Target Audience of the Global BCG Vaccine Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors